Skip to content

Company newsroom

Actinium Pharmaceuticals, Inc.

NYSE AMERICAN:ATNM

2 releases

Actinium Pharmaceuticals, Inc.Nov 4, 2026

Actinium Pharmaceuticals Announces Three ASH 2026 Abstracts Highlighting Iomab-ACT Clinical Results in CAR T-Cell Therapy and Sickle Cell Disease

The three abstracts strengthen the clinical foundation for Iomab-ACT's development as a targeted conditioning platform for cellular and gene…

Actinium Pharmaceuticals, Inc.Nov 2, 2026

Actinium Pharmaceuticals Announces Acceptance of ATNM-400 Abstract for Presentation at SABCS 2026 Highlighting Activity Across Therapy-Resistant Breast Cancer Models

Poster presentation to highlight preclinical efficacy of ATNM-400 across therapy-resistant breast cancer subtypes ATNM-400 is a first-in-class…